Results 1 to 10 of about 181,087 (306)

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation

Frontiers in Immunology, 2022
Co-stimulation is critical to the function of chimeric antigen receptor (CAR) T-cells. Previously, we demonstrated that dual co-stimulation can be effectively harnessed by a parallel (p)CAR architecture in which a CD28-containing second generation CAR is
Leena Halim, Kushal K. Das, Daniel Larcombe-Young, Adam Ajina, Andrea Candelli, Reuben Benjamin, Reuben Benjamin, Richard Dillon, Richard Dillon, David M. Davies, John Maher, John Maher, John Maher, John Maher   +13 more
doaj   +1 more source

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens

Nature Communications, 2021
Chimeric antigen receptor T cells in the clinic currently target cell-type-specific extracellular antigens on malignant cells. Here, authors engineer tumor-specific chimeric antigen receptor T cells that target human leukocyte antigen-presented ...
Michael S. Hwang, Michelle S. Miller, Puchong Thirawatananond, Jacqueline Douglass, Katharine M. Wright, Emily Han-Chung Hsiue, Brian J. Mog, Tihitina Y. Aytenfisu, Michael B. Murphy, P. Aitana Azurmendi, Andrew D. Skora, Alexander H. Pearlman, Suman Paul, Sarah R. DiNapoli, Maximilian F. Konig, Chetan Bettegowda, Drew M. Pardoll, Nickolas Papadopoulos, Kenneth W. Kinzler, Bert Vogelstein, Shibin Zhou, Sandra B. Gabelli   +21 more
doaj   +1 more source

Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives

ImmunoMedicine, 2022
Acute myeloid leukemia (AML) is one of the lethal hematological malignancies with high relapse rates and poor prognosis. Since chimeric antigen receptor cellular therapy has exhibited remarkable therapeutic outcomes in B‐cell malignancies, many studies ...
Yue Huang, Mi Shao, Yiyun Wang, He Huang
doaj   +1 more source

Novel Use of Extracorporeal Blood Purification for Treatment of Severe, Refractory Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy—A Case Report

Critical Care Explorations, 2021
BACKGROUND:. Chimeric antigen receptor T-cell therapies (CAR-T) are transforming the treatment of B-cell leukemias and lymphomas. Cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome represent common, potentially life ...
Kai Singbartl, MD, MPH, Allison Rosenthal, DO, Jose Leis, MD, PhD, Bhavesh Patel, MD, Ayan Sen, MD, MSc   +4 more
doaj   +1 more source

CAR-T cell therapy for hematological malignancies: History, status and promise

Heliyon, 2023
For many years, the methods of cancer treatment are usually surgery, chemotherapy and radiation therapy. Although these methods help to improve the condition, most tumors still have a poor prognosis.
Chao Wang, Jianpeng Wang, Shusheng Che, Hai Zhao   +3 more
doaj   +1 more source

An Interesting Similarity of Bacillus Calmette-Guerin and Chimeric Antigen Receptor T Cells

Translational Research in Urology, 2020
Intravesical Bacillus Calmette-Guerin (BCG) is approved for non-muscle invasive bladder cancer treatment a long time ago. Chimeric antigen receptor T cells (CAR-Tcell), are T cells are genetically engineered T cells that produce an artificial T-cell ...
Seyed Saeed Tamehri Zadeh, AhmadReza Rezaeian   +1 more
doaj   +1 more source

Regions of the T cell receptor alpha and beta chains that are responsible for interactions with CD3. [PDF]

, 1991
The T cell antigen receptor consists of the Ti alpha/beta heterodimer which recognizes antigen, and the associated CD3 chains, thought to be involved in signal transduction.
Tan, L, Turner, J, Weiss, A
core   +1 more source

Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy [PDF]

, 2020
Chimeric antigen receptor (CAR) T-cell therapy has produced remarkable anti-tumor responses in patients with B-cell malignancies. However, clonal kinetics and transcriptional programs that regulate the fate of CAR-T cells after infusion remain poorly ...
Adair, Jennifer E., DeBerg, Hannah A., Enstrom, Mark R., Gersuk, Vivian, Gottardo, Raphaël, Hanafi, Laïla-Aïcha, Hawkins, Reed, Kiem, Hans-Peter, Linsley, Peter S., Maloney, David G., Pande, Dnyanada, Riddell, Stanley R., Sheih, Alyssa, Turtle, Cameron J., Voillet, Valentin, Wohlfahrt, Martin E., Yajima, Masanao   +16 more
core   +1 more source

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]

, 1992
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Flieger, Dimitri, Kaluzab, Brigitte, Lenz, Helmut, Reiter, Christian, Rieber, Ernst Peter, Riethmüller, Gert, Scheuer, Werner, Schwirzke, Marina, Weidle, Ulrich H., Weiss, Elisabeth H., Weissenhorn, Winfried   +10 more
core   +1 more source

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. [PDF]

, 2017
BackgroundT cells engineered to express chimeric antigen receptors (CARs) have established efficacy in the treatment of B-cell malignancies, but their relevance in solid tumors remains undefined.
A Molinolo, A Stasi Di, A Thor, B Fisher, BA Irving, BL Levine, C Romeo, CC Kloss, CY Wu, D Moritz, DL Porter, DW Lee, F Guadagni, HM Finney, I Blanco, I Stancovski, J Scholler, JD Wolchok, JL Murray, JN Kochenderfer, JW Greiner, KD Griffith, L Naldini, M Hegde, M Kalos, ME Dudley, MH Finer, MH Kershaw, ML Davila, MR Lander, N Gonzales, NP Restifo, P Hwu, RA Morgan, RE Walker, RF Meredith, RP McGuinness, RT Mitsuyasu, S Guedan, SD Patel, SG Deeks, SL Maude, SV Kashmiri   +42 more
core   +1 more source